報價延遲最少15分鐘:2025/01/21 08:40 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.16 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.65/--
|
|
企業價值
42.04M
|
| 資產負債 |
|
每股賬面淨值
0.37
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
110.75K
|
|
每股收益
0.05
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/21 08:40 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Nexalin Technology Inc designs and develops innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device. |